SIBN · SI-BONE, Inc.
$18.93
-0.02 (-0.11%)
At close · Aug 14
Market Cap
$848.42M
Shares
44.82M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.93
Open$19.01
Day$18.70–19.07
52W close$11.61–21.40
Avg vol 30d521K
Short int5.1M · 11.3% float · 10.9d
Short vol71%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+17%
above
Price vs 50-day avg
+11%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
75%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+21%
trailing
YTD return
−4%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $16 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$979.0K over 90 days · 100% sells
Short interest
Falling
11.34% of float · ▼ -7.7% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
+22%
Y/Y
Gross margin
238%
contracting
EPS growth
+41%
Y/Y
Free cash flow
$-9.1M
Balance sheet
$6.7M
net cash
Quant / Vol
risk profile
Volatility
49%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
3.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
Worldwide revenue
· Fiscal Year 2026
$231M – $233M
Gross Margin
· Fiscal Year 2026
79%
Operating Expenses
· Fiscal Year 2026
12%
Prior guidance
period ended
· from the 8-K filed Nov 10, 2025
Worldwide revenue
· Fiscal Year 2025
$198M – $200M
Gross Margin
· Fiscal Year 2025
79.5%
Guided vs delivered
· last 2 settled
Worldwide revenue
Fiscal Year 2025
guided $198M – $200M
$200.93M
Beat +1.0%
Worldwide revenue
2024
guided $162M – $165M
$167.18M
Beat +2.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+17%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
75%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $16 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$979.0K over 90 days · 100% sells
Short interest
Falling
11.34% of float · ▼ -7.7% MoM · 10.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12
Now $19 · 75%
Range high $21
vs 200-day avg +17%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.8M | second quarter 2026 | — |
|
|
|||
| Active U.S. physicians | 1,650 | First Quarter 2026 | — |
|
|
|||
| Trailing 12-month average revenue per territory | $2.2M | First Quarter 2026 | — |
| Free cash flow non-GAAP | $0.4M | Q4 FY2025 | — |
| U.S. 4Q procedure volume | 6,100 | Q4 FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SIBN
this stock
SI-BONE, Inc.
|
$848.42M | -4.0% | +21.5% | — | 11.3% |
|
ABT
Abbott Laboratories
|
$194.07B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SIBN | +1.7% | +8.9% | +21.2% | +6.6% | -4.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.3% | +4.5% | +7.4% | +2.7% | -17.9% |
Key facts
CIK
1459839
CUSIP
825704109
13F (30d)
168 filings
165 filers
Visit website
Investor relations